Medical Patent News

RSS

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans Carotenoids, Their Synthesis and Uses," respectively.

16 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

USPTO issues patent to Aeterna Zentaris’ AEZS-130 oral test for AGHD

Aeterna Zentaris Inc. today announced that the United States Patent and Trademark Office has granted a patent for the use of its oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency.

7 Aug 2012

Applied BioCode receives U.S. patent for ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United Stated Patent and Trademark Office has granted US Patent #8,232,092 "Light Transmitted Assay Beads," describing the method of decoding barcodes and analyzing bioassays using Barcoded Magnetic Beads (BMB) multiplex products.

7 Aug 2012

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.

6 Aug 2012

Eliza receives U.S. patent allowance for Complex Acoustic Resonance Speech Analysis System

Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a Complex Acoustic Resonance Speech Analysis System.

6 Aug 2012

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company's lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.

30 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation.

20 Jul 2012

Quick-Med Technologies grants Derma Sciences global license to NIMBUS antimicrobial technology

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, and Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announce the signing of an agreement whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to the novel NIMBUS antimicrobial technology, which is available in BIOGUARD dressings.

13 Jul 2012

U.K. High Court rules in favor of Teva in COPAXONE patent litigation

Teva Pharmaceutical Industries Ltd. announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012.

12 Jul 2012

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

10 Jul 2012

AtheroNova receives U.S. patent allowance for 'Dissolution of Arterial Plaque'

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that it has received a Notice of Allowance for its patent application for Dissolution of Arterial Plaque.

10 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

UPM researchers develop a functional biscuit for celiac patients

Researchers at the Universidad Politécnica de Madrid (UPM) have patented a biscuit which is made from teff flour, suitable for celiac patients, and, thanks to its nutritional properties, it is ideal for sportsmen, diabetics and people with anemia.

4 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

The US Patent and Trademark Office has issued a patent supporting a long-term, multi-year research and development collaboration between Mount Sinai School of Medicine (MSSM) and Humanetics Corporation to develop and commercialize a safe and effective means to prevent or slow the progression of Alzheimer's disease. Humanetics is the exclusive licensee for this patent.

28 Jun 2012

Medical Patent News

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

BioDiem granted European patent for antimicrobial drug

USPTO issues patent to Aeterna Zentaris’ AEZS-130 oral test for AGHD

Applied BioCode receives U.S. patent for ‘Light Transmitted Assay Beads’

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Eliza receives U.S. patent allowance for Complex Acoustic Resonance Speech Analysis System

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

ACT receives Australian patent for human retinal pigment epithelial cells

Illumina sues IBS and Qiagen for infringement of three patents

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Quick-Med Technologies grants Derma Sciences global license to NIMBUS antimicrobial technology

U.K. High Court rules in favor of Teva in COPAXONE patent litigation

ImmunoCellular receives Japanese patent allowance for brain cancer technology

AtheroNova receives U.S. patent allowance for 'Dissolution of Arterial Plaque'

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

Treatment of Schizophrenia receives notice of intention to grant a European patent

UPM researchers develop a functional biscuit for celiac patients

USPTO issues notice of allowance to Avanir for NUEDEXTA

CytRx granted European patent for tumor-targeting linker platform technology

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News